# Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.

> **NCT00262678** · PHASE3 · COMPLETED · sponsor: **Kyowa Kirin Co., Ltd.**

## Conditions studied

- Pain
- Cancer

## Interventions

- **DRUG:** EN3267

## Key facts

- **NCT ID:** NCT00262678
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2008-12
- **Final completion:** 2009-01
- **Target enrollment:** — (—)
- **Last updated:** 2009-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00262678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00262678, "Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00262678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*